NO973385L - Lymfotoksin-<alfa>/<beta>-komplekser og anti-lymfotoksin-beta-reseptor-antistoff som anti-svulstmidler - Google Patents

Lymfotoksin-<alfa>/<beta>-komplekser og anti-lymfotoksin-beta-reseptor-antistoff som anti-svulstmidler

Info

Publication number
NO973385L
NO973385L NO973385A NO973385A NO973385L NO 973385 L NO973385 L NO 973385L NO 973385 A NO973385 A NO 973385A NO 973385 A NO973385 A NO 973385A NO 973385 L NO973385 L NO 973385L
Authority
NO
Norway
Prior art keywords
beta
activating agent
lymphotoxin
lhc
carrier
Prior art date
Application number
NO973385A
Other languages
English (en)
Other versions
NO322744B1 (no
NO973385D0 (no
Inventor
Jeffrey L Browning
Werner Meier
Christopher D Benjamin
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of NO973385D0 publication Critical patent/NO973385D0/no
Publication of NO973385L publication Critical patent/NO973385L/no
Publication of NO322744B1 publication Critical patent/NO322744B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO19973385A 1995-01-26 1997-07-22 Anvendelse av Lymfotoksin-alfa/beta-komplekser til fremstilling av medikamenter mot neoplasia samt anti-lymfotoksin-beta-reseptor-antistoff som anti-svukstmidler. NO322744B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37896895A 1995-01-26 1995-01-26
PCT/US1996/001386 WO1996022788A1 (en) 1995-01-26 1996-01-26 LYMPHOTOXIN-α/β COMPLEXES AND ANTI-LYMPHOTOXIN-BETA RECEPTOR ANTIBODIES AS ANTI-TUMOR AGENTS

Publications (3)

Publication Number Publication Date
NO973385D0 NO973385D0 (no) 1997-07-22
NO973385L true NO973385L (no) 1997-09-25
NO322744B1 NO322744B1 (no) 2006-12-04

Family

ID=23495285

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19973385A NO322744B1 (no) 1995-01-26 1997-07-22 Anvendelse av Lymfotoksin-alfa/beta-komplekser til fremstilling av medikamenter mot neoplasia samt anti-lymfotoksin-beta-reseptor-antistoff som anti-svukstmidler.

Country Status (24)

Country Link
EP (2) EP0809510B1 (no)
JP (2) JPH10513161A (no)
KR (2) KR100475492B1 (no)
CN (3) CN1900116A (no)
AT (1) ATE268604T1 (no)
AU (1) AU725351B2 (no)
BG (1) BG62599B1 (no)
BR (1) BR9606808A (no)
CA (1) CA2211443A1 (no)
CZ (1) CZ298711B6 (no)
DE (1) DE69632681T2 (no)
DK (1) DK0809510T3 (no)
EA (1) EA000096B1 (no)
EE (1) EE04453B1 (no)
ES (1) ES2220972T3 (no)
FI (1) FI119359B (no)
HU (1) HUP9801746A3 (no)
NO (1) NO322744B1 (no)
NZ (1) NZ303405A (no)
PL (1) PL185364B1 (no)
PT (1) PT809510E (no)
RO (1) RO118634B1 (no)
SK (1) SK286497B6 (no)
WO (1) WO1996022788A1 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6140467A (en) * 1997-07-07 2000-10-31 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US7118742B2 (en) 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
KR100888832B1 (ko) 1998-10-09 2009-03-17 바이오겐 아이덱 엠에이 인코포레이티드 림프독소 베타 경로의 차단에 의한 바이러스-유도성 전신 쇼크 및 호흡 장애의 반전
EP1326897A2 (en) * 2000-10-13 2003-07-16 Biogen, Inc. Humanized anti-lt-beta-r antibodies
CN1678625A (zh) * 2002-07-01 2005-10-05 比奥根艾迪克Ma公司 人源化抗淋巴毒素β受体的抗体
KR20050094819A (ko) * 2002-12-20 2005-09-28 바이오겐 아이덱 엠에이 인코포레이티드 화학요법제와 조합된 림프독소 베타 수용체 약제
WO2004058191A2 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
CA2530388A1 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
JP2007530588A (ja) 2004-03-23 2007-11-01 バイオジェン・アイデック・エムエイ・インコーポレイテッド レセプターカップリング剤およびその治療用途
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
EP1764371A1 (de) * 2005-04-25 2007-03-21 Xantos Biomedicine AG Agonistische Antikörper, welche an den LT-Beta-Rezeptor binden und dadurch Adipositas assoziierte Phänotypen modulieren, und deren Verwendung in der Therapie
CN101073665B (zh) * 2006-05-17 2014-11-26 上海复旦张江生物医药股份有限公司 淋巴毒素在制备增加化疗药物敏感性的药物中的应用
WO2008042436A2 (en) 2006-10-03 2008-04-10 Biogen Idec Ma Inc. Biomarkers and assays for the treatment of cancer
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
AU2007311052B2 (en) 2006-10-20 2014-01-16 Biogen Idec Ma Inc. Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
CA2737379A1 (en) * 2008-09-30 2010-04-08 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to lymphotoxin antagonists
MX2014006739A (es) * 2011-12-05 2015-06-05 Igenica Biotherapeutics Inc Conjugados de anticuerpo-farmaco y compuestos relacionados, composiciones , y metodos.
DK3247728T3 (da) 2015-01-20 2020-07-13 Igm Biosciences Inc Tumornekrosefaktor-(tnf)-superfamiliereceptorbindende molekyler og anvendelser deraf
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
US20240018248A1 (en) 2020-12-02 2024-01-18 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2023198848A1 (en) 2022-04-13 2023-10-19 Vib Vzw An ltbr agonist in combination therapy against cancer
AR134514A1 (es) 2023-12-01 2026-01-21 Gilead Sciences Inc Proteína de fusión anti-fap-ligera y uso de esta

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6124599A (ja) * 1984-07-11 1986-02-03 Kyowa Hakko Kogyo Co Ltd 新規ヒトインタ−フエロン−ｒポリペプチド誘導体
JPS61277628A (ja) * 1985-06-04 1986-12-08 Asahi Chem Ind Co Ltd 癌治療用白血球刺激材
US4770995A (en) * 1985-08-29 1988-09-13 New York Blood Center, Inc Detection of the sensitivity of cells to the effects of tumor necrosis factor and lymphotoxin
EP0536299B1 (en) * 1990-06-27 2001-06-06 Biogen, Inc. Surface complexed lymphotoxin
AU692146B2 (en) * 1990-06-27 1998-06-04 Biogen Idec Ma Inc. Lymphotoxin-beta, lymphotoxin-beta complexes, pharmaceutical preparations and therapeutic uses thereof

Also Published As

Publication number Publication date
KR100475492B1 (ko) 2005-03-14
MX9705629A (es) 1997-10-31
RO118634B1 (ro) 2003-08-29
SK98697A3 (en) 2000-02-14
DK0809510T3 (da) 2004-10-04
EA199700144A1 (ru) 1997-12-30
AU4970496A (en) 1996-08-14
DE69632681T2 (de) 2005-06-09
SK286497B6 (sk) 2008-11-06
ES2220972T3 (es) 2004-12-16
CZ236197A3 (cs) 1998-02-18
BG62599B1 (bg) 2000-03-31
HK1006356A1 (en) 1999-02-26
KR19980701816A (ko) 1998-06-25
EP1407781A1 (en) 2004-04-14
KR20040102364A (ko) 2004-12-04
CN1589902A (zh) 2005-03-09
CA2211443A1 (en) 1996-08-01
EE9700255A (et) 1998-04-15
JP2007169296A (ja) 2007-07-05
CZ298711B6 (cs) 2008-01-02
EA000096B1 (ru) 1998-08-27
FI973118A0 (fi) 1997-07-25
DE69632681D1 (de) 2004-07-15
BR9606808A (pt) 1997-12-30
CN1146442C (zh) 2004-04-21
NO322744B1 (no) 2006-12-04
EP0809510A1 (en) 1997-12-03
AU725351B2 (en) 2000-10-12
PT809510E (pt) 2004-09-30
EP0809510B1 (en) 2004-06-09
WO1996022788A1 (en) 1996-08-01
HUP9801746A2 (hu) 1998-11-30
ATE268604T1 (de) 2004-06-15
JPH10513161A (ja) 1998-12-15
HUP9801746A3 (en) 2000-11-28
CN1177302A (zh) 1998-03-25
NZ303405A (en) 2000-02-28
NO973385D0 (no) 1997-07-22
BG101855A (en) 1998-04-30
PL185364B1 (pl) 2003-04-30
KR100470739B1 (ko) 2005-09-02
CN1900116A (zh) 2007-01-24
FI973118A7 (fi) 1997-09-25
FI119359B (fi) 2008-10-31
EE04453B1 (et) 2005-04-15
PL321758A1 (en) 1997-12-22

Similar Documents

Publication Publication Date Title
NO973385L (no) Lymfotoksin-&lt;alfa&gt;/&lt;beta&gt;-komplekser og anti-lymfotoksin-beta-reseptor-antistoff som anti-svulstmidler
PL331091A1 (en) Therapeutic multispecific compounds encompassing antibodies against the fcalpha receptor
AU9779498A (en) Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
MX9709324A (es) Compuestos terapeuticos que comprenden anticuerpos anti receptores fc.
GR3007225T3 (no)
IL180924A0 (en) Method for regulating cell proliferation and cell death
EP0553244B8 (en) Targeted immunostimulation with bispecific reagents
YU83600A (sh) Adenozin a3 receptorski modulatori
DE97905729T1 (de) Als 2f1 bezeichnetes rezeptorprotein
TR199801255T2 (xx) Vitronektin resept�r antagonistleri.
AU7478394A (en) Methods for (ex vivo) therapy using peptide-loaded antigen presenting cells for the activation of ctl
PT983286E (pt) Compostos de aminoalquil-glicosamina-fosfato e sua utilizacao como adjuvantes eimunoefectores
DE69032979D1 (de) Bispezifische heteroantikörper mit zweifachen effektorfunktionen
MY108526A (en) Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
NO970740L (no) Glutamat reseptor
NO965395L (no) Humane, monoklonale antistoffer som er spesifikke mot cellecyklus-uavhengig gliom-overflateantigen
AR021353A1 (es) Proceso para el procesamiento de sacarosa en glucosa.
NO982588D0 (no) FremgangsmÕte for diagnose og behandling av plate epizelkarsinom
WO1997041225A3 (en) Mammalian mixed lymphocyte receptors, chemokine receptors [mmlr-ccr]
EP1144666A3 (en) Replication deficient baculovirus expression system
MX9302549A (es) Proteina receptora especifica para la region csvt cg de la trombospondina y metodo para su purificacion y caracterizacion.
TR200103288T2 (tr) Tio-oksindol türevleri
ATE40116T1 (de) 1-acyl-3-pyridylmethylguanidine und deren verwendung als antihypertensiva.
DK0943014T3 (da) Fremgangsmåder til diagnosticering af glaukom og opdagelse af antiglaukome lægemidler
NO965347L (no) Fremgangsmåte for fremstilling av cytolytiske T-celler som er spesifikke for et peptid/MHC-kompleks

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees